エムバイオテック


			Corporate philosophy
			M Bio Technology Inc. is the research-and-development type venture business established on January 5, 2005. M Bio Technology Inc. is focusing the diagnosis, therapeutic and prevention with Mycoplasma Infectious Diseases. Mycoplasma infection cause not only pneumonia but asthma, arthritis, nephritis, meningitis, encephalitis, arteritis, dermatitis, etc., and presents variegated condition, such as autoimmune diseases, rheumatic disease and a nervous system disorders, innflammatory diseases. M Bio Technology Inc. is aiming for bussiness development on the mycoplasma lipid-antigen technologies.The diagnosis and drug design to the pathogenic microbe using the synthesized lipid antigen are world's first platform technology, and, would like to explore mutual business opportunities, in the field of diagnostics and vaccines. We would like to create an open innovation and global development are promoted, and wish joint development, a business tie-up, and the information and support relevant to a finance.

			Kazuhiro Matsuda, M.D.,Ph.D. Director of Mycoplasma Infectious Diseases Research Center (MIDRC), M Bio Technology Inc Education 1985 M.D. : Yamaguchi University School of Medicine 1990 Ph.D. : Yamaguchi University School of Medicine, International Medicine Professional Experience 1993-1998 Assistant Professor : Dept. of Microbiology of Tokyo Medical and Dental University 1997-1998 Special Volunteer : Laboratory of Biophysical Chemistry, National Heart, Lung and Blood Institute, National Institute of Health 1998-2005 Senior Scientist : National Cancer Center Reseach Institute 2005- CSO & Director : M Bio Technology Inc. 2005-2011 Visiting Scientist : National Institute of Advanced Industrial Science and Technology 2012- Director : Mycoplasma Infectious Diseases Research Center (MIDRC), M Bio Technology Inc.